AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

Zacks
Apri Zacks
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing proteinuria (protein in urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Following the latest nod, Ultomiris became the first and only C5 complement inhibitor to be approved in the United States for this indication.

The indication is approved under the FDA's accelerated approval pathway and is based on the reduction in proteinuria. It has not yet been established whether Ultomiris slows kidney function decline in patients with IgAN. The ongoing phase III I CAN study is evaluating changes in estimated glomerular filtration rate (eGFR) at week 106, with results intended to support traditional FDA approval.

Year to date, shares of AstraZeneca have declined 7.4% against the industry’s increase of 6.7%.

Zacks Investment Research
Image Source: Zacks Investment Research

FDA Nod Based on AZN’s Late-Stage I CAN Study

The FDA approval was based on interim data from the phase III I CAN study, which showed that treatment with Ultomiris for 34 weeks led to a statistically significant and clinically meaningful reduction in proteinuria. Per AstraZeneca, Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo.

The safety profile of Ultomiris in the study was consistent with its established profile, with no new safety concerns identified.

Ultomiris is administered intravenously every eight weeks following a loading dose, with dosing based on body weight. The latest approval marks its fifth indication in the United States, expanding its use across complement-mediated diseases.

The drug is currently approved in the United States, Europe and Japan across four indications. These include atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) and paroxysmal nocturnal hemoglobinuria (PNH).

In the first six months of 2026, Ultomiris generated $2.58 billion in sales, up 14% year over year, driven by strong demand across approved indications, geographic expansion and continued patient conversion from Soliris.

AZN’s Competition in the IgAN Space

Ultomiris is likely to compete with Calliditas Therapeutics’ Tarpeyo, Novartis’ NVS Fabhalta and Travere Therapeutics’ TVTX Filspari.

Both Calliditas’ Tarpeyo and Travere’s Filspari are approved for a similar indication — slowing the decline in kidney function in adults with primary IgAN who are at risk of disease progression.

Novartis’ Fabhalta is approved under the accelerated pathway for reducing proteinuria in adults with primary IgAN who are at risk of rapid disease progression. The NVS drug is also approved for complement 3 glomerulopathy and PNH indications.

AZN’s Zacks Rank

AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
AstraZeneca PLC (AZN): Free Stock Analysis Report
 
Novartis AG (NVS): Free Stock Analysis Report
 
Travere Therapeutics, Inc. (TVTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research